EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients

Mohamed Ali Badawi, Benjamin Engelhardt, Edyta Dobkowska, Rong Deng, Jonathan L Kaufman, Rajeev Menon, Ahmed Hamed Salem

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01471-x ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Mohamed Ali Badawi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA. mohamed.badawi@abbvie.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax is a first in class BCL-2 inhibitor, currently under investigation for the treatment of t(11;14) multiple myeloma (MM). The objective of this analysis was to characterize the exposure-efficacy and exposure-safety relationships of venetoclax when combined with carfilzomib and dexamethasone (VenKd) in t(11;14)-positive relapsed or refractory (R/R) MM patients from a phase 2 study. Fifty-seven patients receiving VenKd or Kd were included in the analysis. Efficacy endpoints included progression-free survival and clinical response rates of overall response, very good partial response or better and complete response or better. Grade ≥ 3 neutropenia, Grade ≥ 3 infections, Grade ≥ 3 treatment-emergent adverse events and any grade serious treatment-emergent adverse events were evaluated. The analysis demonstrated that adding venetoclax to Kd resulted in increased ORR, ≥VGPR and ≥ CR rates compared to the control arm. Within the venetoclax treatment arms (VenKd), no significant exposure-efficacy relationships were observed for ORR and ≥ VGPR rates. Higher ≥ CR rates trended with higher venetoclax exposures. While both 400 mg and 800 mg venetoclax in VenKd arms were generally tolerated, higher rates of Grade ≥ 3 neutropenia were observed with higher venetoclax exposures. Higher venetoclax exposures however were not associated with increased rates of Grade ≥ 3 treatment-emergent adverse events, Grade ≥ 3 infections, or serious treatment-emergent adverse events (any grade). These results confirm the benefit of adding venetoclax to carfilzomib and dexamethasone and support continued evaluation of venetoclax 400-800 mg once daily in this combination in t(11;14)-positive R/R MM patients. NCT02899052 registered April 18, 2017.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaDexamethasoneBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsOligopeptidesHumansMiddle AgedMaleFemaleAgedAdultAged, 80 and overChromosomes, Human, Pair 14Chromosomes, Human, Pair 11Translocation, Genetic

Stichwörter der Autor:innen

CarfilzomibDose selectionExposure-responseMultiple myelomaRelapsed/refractoryVenetoclax

Substanzen

venetoclaxcarfilzomibDexamethasoneBridged Bicyclo Compounds, HeterocyclicSulfonamidesOligopeptides

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA. mohamed.badawi@abbvie.com.
  • Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
  • Oncology Development, AbbVie, Pharmacyclics, Schaffhausen, Switzerland.
  • Genentech, Inc, South San Francisco, CA, USA.
  • Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA.
  • Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.

Förderung

  • AbbVie
  • Genentech

Zitieren

APA

Badawi, M. A., Engelhardt, B., Dobkowska, E., Deng, R., Kaufman, J. L., Menon, R., & Salem, A. H. (2024). Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01471-x

Vancouver

Badawi MA, Engelhardt B, Dobkowska E, Deng R, Kaufman JL, Menon R, et al. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01471-x

BibTeX
@article{Badawi2024,
  author = {Badawi, Mohamed Ali and Engelhardt, Benjamin and Dobkowska, Edyta and Deng, Rong and Kaufman, Jonathan L and Menon, Rajeev and Salem, Ahmed Hamed},
  title = {Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01471-x}
}
Kostenlos starten →